Home › Research › Down syndrome and Alzheimer's
Enhancement of neurogenesis and memory by a neurotrophic peptide in mild to moderate traumatic brain injury
Chohan MO, Bragina O, Kazim SF, Statom G, Baazaoui N, Bragin D, Iqbal K, Nemoto E et al.. Neurosurgery, 2015-02-01
Topic: Brain proteins, microglia and lab models
Plain-language summary
Background Traumatic brain injury (TBI) is a risk factor for Alzheimer disease (AD), a neurocognitive disorder with similar cellular abnormalities. We recently discovered a small molecule (Peptide 6) corresponding to an active region of human ciliary neurotrophic factor, with neurogenic and neurotrophic properties in mouse models of AD and Down syndrome. Objective To describe hippocampal abnormalities in a mouse model of mild to moderate TBI and their reversal by Peptide 6. Methods TBI was induced in adult C57Bl6 mice using controlled cortical impact with 1.5 mm of cortical penetration. The animals were treated with 50 nmol/d of Peptide 6 or saline solution for 30 days. Dentate gyrus neurogenesis, dendritic and synaptic density, and AD biomarkers were quantitatively analyzed, and behavioral tests were performed. Results Ipsilateral neuronal loss in CA1 and the parietal cortex and increase in Alzheimer-type hyperphosphorylated tau and A-β were seen in TBI mice. Compared with saline solution, Peptide 6 treatment increased the number of newborn neurons, but not uncommitted progenitor cells, in dentate gyrus by 80%. Peptide 6 treatment also reversed TBI-induced dendritic and synaptic density loss while increasing activity in tri-synaptic hippocampal circuitry, ultimately leading to improvement in memory recall on behavioral testing. Conclusion Long-term treatment with Peptide 6 enhances the pool of newborn neurons in the dentate gyrus, prevents neuronal loss in CA1 and parietal cortex, preserves the dendritic and synaptic architecture in the hippocampus, and improves performance on a hippocampus-dependent memory task in TBI mice. These findings necessitate further inquiry into the therapeutic potential of small molecules based on neurotrophic factors.
What this study adds
Evidence grade: Low
In a mouse model of traumatic brain injury, a neurotrophic peptide increased newborn neurons and improved memory recall. These are animal results only, and the authors state that further inquiry into the therapeutic potential of such small molecules is needed.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Chohan, M. O., Bragina, O., Kazim, S. F., Statom, G., Baazaoui, N., Bragin, D., et al. (2015). Enhancement of neurogenesis and memory by a neurotrophic peptide in mild to moderate traumatic brain injury. Neurosurgery. https://doi.org/10.1227/neu.0000000000000577
Vancouver
Chohan MO, Bragina O, Kazim SF, Statom G, Baazaoui N, Bragin D, et al. Enhancement of neurogenesis and memory by a neurotrophic peptide in mild to moderate traumatic brain injury. Neurosurgery. 2015. doi:10.1227/neu.0000000000000577. PMID: 25255260.
BibTeX
@article{chohan2015-25255260,
author = {Chohan, M. O. and Bragina, O. and Kazim, S. F. and Statom, G. and Baazaoui, N. and Bragin, D. and Iqbal, K. and Nemoto, E. and others},
title = {{Enhancement of neurogenesis and memory by a neurotrophic peptide in mild to moderate traumatic brain injury}},
journal = {Neurosurgery},
year = {2015},
doi = {10.1227/neu.0000000000000577},
pmid = {25255260},
url = {https://doi.org/10.1227/neu.0000000000000577}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Results Ipsilateral neuronal loss in CA1 and the parietal cortex and increase in Alzheimer-type hyperphosphorylated tau and A-β were seen in TBI mice.
- Compared with saline solution, Peptide 6 treatment increased the number of newborn neurons, but not uncommitted progenitor cells, in dentate gyrus by 80%.
- These findings necessitate further inquiry into the therapeutic potential of small molecules based on neurotrophic factors.
Why it matters
In a mouse model of traumatic brain injury, a neurotrophic peptide increased newborn neurons and improved memory recall. These are animal results only, and the authors state that further inquiry into the therapeutic potential of such small molecules is needed.
Study details
- Evidence strengthLow
How this study scored 35/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Neurosurgery) |
| Journal's citation record | 3 / 4 | Neurosurgery: journal h-index 300 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2015 — within 20 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 3 / 7 | Cited 29 times (OpenAlex, 2026-10-10) |
| Citations per year | 1 / 5 | 2.2 citations a year over 13 year(s) since 2015 |
| Impact for its field and year | 2 / 6 | Cited 2.3× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 1 / 4 | Cited 3 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Howard Yonas: h-index 41 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | State University of New York: institution h-index 747 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 3 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 25255260) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 35 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1227/neu.0000000000000577
- PubMed: 25255260
- Original source →
- Free full text: PubMed Central →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Down syndrome and Alzheimer's from nearby years
Also tagged “down”
527 studies in the library carry the topic tag “down”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 527 tagged studies.